Hong Kong
# |
Name |
Total Non-Current Liabilities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 133.36 M
|
Dec. 31, 2023 | USD 2.68 | -1.44% |
|
Hong Kong |
|
2 |
USD 127.14 M
|
Dec. 31, 2023 | USD 0.22 | -1.18% |
|
Hong Kong |
|
3 |
USD 38.32 M
|
Dec. 31, 2023 | USD 0.37 | 4.31% |
|
Hong Kong |
|
4 |
USD 36.01 M
|
Dec. 31, 2023 | USD 0.16 | -3.21% |
|
Hong Kong |
|
5 |
USD 4.53 M
|
Dec. 31, 2023 | USD 5.25 | -2.96% |
|
Hong Kong |
The Clinical Trials company in Hong Kong with the highest Total Non-Current Liabilities is HUTCHMED (China) Limited (HKSE: 0013.HK) at USD 133.36 M.
The Clinical Trials company in Hong Kong with the lowest Total Non-Current Liabilities is Prenetics Global Limited (NasdaqGM: PRE) at USD 4.53 M.
The top 10 Clinical Trials companies in Hong Kong by Total Non-Current Liabilities are HUTCHMED (China) Limited, Frontage Holdings Corporation, Sirnaomics Ltd., Lee's Pharmaceutical Holdings Limited and Prenetics Global Limited.
The bottom 10 Clinical Trials companies in Hong Kong by Total Non-Current Liabilities are Prenetics Global Limited, Lee's Pharmaceutical Holdings Limited, Sirnaomics Ltd., Frontage Holdings Corporation and HUTCHMED (China) Limited.